Global Breast Cancer Monoclonal Antibodies Market Outlook 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Breast cancer incidences are increasing across the globe and conventional therapeutics have modest pharmacological efficacy. To surmount this issue, investigators came forth with monoclonal antibodies for breast cancer treatment which have targeted capabilities along with higher safety and efficacy levels. They have found that some receptors have overexpressed in cancerous cells due to which they could be identified and targeted. Monoclonal antibodies are highly customizable due to specific nature they eliminate cancerous cells while sparing normal cells during breast cancer treatment. Their use in neoadjuvant and adjuvant therapy has been successfully checked by investigators. Some the breast cancer monoclonal antibodies are also used in first-line and second-line treatment. Moreover, they are also compatible with chemotherapeutics due to which they are commonly used in combinatorial therapy. In future, investigators are expected to find new monoclonal antibody formulations offering better medical care to breast cancer patients.
Breast cancer segment consists of few monoclonal antibodies and chemotherapeutics seems to dominate the landscape. Hormone therapy and kinase inhibitors are other major segment which has been widely prescribed by physicians. Emerging technologies, personalized breast cancer vaccine, has also started to make niche in breast cancer segment. This scenario reflects that breast cancer monoclonal antibodies have to witness severe competition in global market. Despite lesser in number, they generate significant revenues due to which pharmaceutical companies are actively engaged in their research and development. They have decreased the market shares of chemotherapeutics and significantly decreased the profit margins of other drug categories. They are likely to dominate the breast cancer segment as they have been accepted as mainstream treatment and they have also become indispensible part of combinatorial therapies.
Globally, Roche seems to dominate the breast cancer monoclonal antibody segment because of largest inventory. Its block buster molecule, Herceptin has been able to dominate this segment for several years. It was found that breast cancer cells become recalcitrant and relapsed condition could not be treated with Herceptin. This finding propelled the development of other monoclonal antibodies to overcome these shortcomings. They have been formulated using variants of Her 2 that has been found to be associates with around quarter of breast cancer cases. They are also used in various combinations due to which they have been able to increase the survival rates and progression free disease survival. On the other hand, introduction of different products by same company for same cancer indication has created competition within the products. As a result, few products generate more sales as compared to other like Herceptin while products like Perjeta which are used in second line treatment generate modes sales.
India, Europe and Australia have been proposed as major market where biosimilar breast cancer monoclonal antibodies would be marketed in incipient stages. These market have different characteristic features due to which they are expected to witness different sales of biosimilar breast cancer monoclonal antibodies. Europe is likely to become an important market due to stringent healthcare budget and maintenance of sustainable healthcare system. European Medicine Agency (EMA) have already granted marketing approval to many biosimilar products. This shows that biosimilar breast cancer monoclonal antibodies are likely to generate significant revenues in European market. Indian market may face slightly slow market growth due to patent issues. However, such issues are expected to be resolved in coming years leading to higher sales. Large population size and escalating breast cancer incidences along with affordable pricing are expected to generate more sales of biosimilar breast cancer monoclonal antibodies. Australia has also shown positive response for these drugs and they are like to import it from countries like India where high production could be achieved at competitive pricing. US market is also likely to open in coming years due to which this category would observe significant growth. In this way, the future of breast cancer monoclonal antibodies seems to be optimistic.
'Global Breast Cancer Monoclonal Antibodies Market Outlook 2020' Report Highlights:
Breast cancer incidences are increasing across the globe and conventional therapeutics have modest pharmacological efficacy. To surmount this issue, investigators came forth with monoclonal antibodies for breast cancer treatment which have targeted capabilities along with higher safety and efficacy levels. They have found that some receptors have overexpressed in cancerous cells due to which they could be identified and targeted. Monoclonal antibodies are highly customizable due to specific nature they eliminate cancerous cells while sparing normal cells during breast cancer treatment. Their use in neoadjuvant and adjuvant therapy has been successfully checked by investigators. Some the breast cancer monoclonal antibodies are also used in first-line and second-line treatment. Moreover, they are also compatible with chemotherapeutics due to which they are commonly used in combinatorial therapy. In future, investigators are expected to find new monoclonal antibody formulations offering better medical care to breast cancer patients.
Breast cancer segment consists of few monoclonal antibodies and chemotherapeutics seems to dominate the landscape. Hormone therapy and kinase inhibitors are other major segment which has been widely prescribed by physicians. Emerging technologies, personalized breast cancer vaccine, has also started to make niche in breast cancer segment. This scenario reflects that breast cancer monoclonal antibodies have to witness severe competition in global market. Despite lesser in number, they generate significant revenues due to which pharmaceutical companies are actively engaged in their research and development. They have decreased the market shares of chemotherapeutics and significantly decreased the profit margins of other drug categories. They are likely to dominate the breast cancer segment as they have been accepted as mainstream treatment and they have also become indispensible part of combinatorial therapies.
Globally, Roche seems to dominate the breast cancer monoclonal antibody segment because of largest inventory. Its block buster molecule, Herceptin has been able to dominate this segment for several years. It was found that breast cancer cells become recalcitrant and relapsed condition could not be treated with Herceptin. This finding propelled the development of other monoclonal antibodies to overcome these shortcomings. They have been formulated using variants of Her 2 that has been found to be associates with around quarter of breast cancer cases. They are also used in various combinations due to which they have been able to increase the survival rates and progression free disease survival. On the other hand, introduction of different products by same company for same cancer indication has created competition within the products. As a result, few products generate more sales as compared to other like Herceptin while products like Perjeta which are used in second line treatment generate modes sales.
India, Europe and Australia have been proposed as major market where biosimilar breast cancer monoclonal antibodies would be marketed in incipient stages. These market have different characteristic features due to which they are expected to witness different sales of biosimilar breast cancer monoclonal antibodies. Europe is likely to become an important market due to stringent healthcare budget and maintenance of sustainable healthcare system. European Medicine Agency (EMA) have already granted marketing approval to many biosimilar products. This shows that biosimilar breast cancer monoclonal antibodies are likely to generate significant revenues in European market. Indian market may face slightly slow market growth due to patent issues. However, such issues are expected to be resolved in coming years leading to higher sales. Large population size and escalating breast cancer incidences along with affordable pricing are expected to generate more sales of biosimilar breast cancer monoclonal antibodies. Australia has also shown positive response for these drugs and they are like to import it from countries like India where high production could be achieved at competitive pricing. US market is also likely to open in coming years due to which this category would observe significant growth. In this way, the future of breast cancer monoclonal antibodies seems to be optimistic.
'Global Breast Cancer Monoclonal Antibodies Market Outlook 2020' Report Highlights:
- Breast Cancer Monoclonal Antibodies Mechanism
- Global Breast Cancer Monoclonal Antibody Market Analysis
- Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
- Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
- Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
- Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
- Bevacizumab (Avastin)
- Pertuzumab (Omnitarg, Perjeta)
- Trastuzumab (Herceptin)
- Trastuzumab Biosimilar (Hertraz & CANMAb)
- Trastuzumab Emtansine (Kadcyla)
- Trastuzumab Subcutaneous (Herceptin)
1. INTRODUCTION TO MONOCLONAL ANTIBODIES
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies
2. NEED FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
3. BREAST CANCER MONOCLONAL ANTIBODIES MECHANISM
4. GLOBAL BREAST CANCER MONOCLONAL ANTIBODY MARKET ANALYSIS
4.1 Current Market Scenario
4.2 Breast Cancer Pipeline Overview
5. GLOBAL BREAST CANCER MONOCLONAL ANTIBODY MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. GLOBAL BREAST CANCER MONOCLONAL ANTIBODIES MARKET FUTURE PROSPECTS
7. BREAST CANCER MONOCLONAL ANTIBODIES PIPELINE BY COMPANY & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase III
7.9 Registered
8. MARKETED BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
8.1 Bevacizumab (Avastin)
8.2 Pertuzumab (Omnitarg, Perjeta)
8.3 Trastuzumab (Herceptin)
8.4 Trastuzumab Biosimilar (Hertraz & CANMAb)
8.5 Trastuzumab Emtansine (Kadcyla)
8.6 Trastuzumab Subcutaneous (Herceptin)
9. DISCONTINUED & SUSPENDED BREAST CANCER MONOCLONAL ANTIBODIES PIPELINE BY COMPANY & PHASE
9.1 Discontinued
9.2 No Development Reported
10. COMPETITIVE LANDSCAPE
10.1 Amgen
10.2 Biocad
10.3 Biocon
10.4 Celltrion Pharm
10.5 CuraGen Corporation
10.6 Dyax Corp
10.7 GlaxoSmithKline
10.8 ImmunoGen
10.9 MacroGenics
10.10 Merck
10.11 Merrimack Pharmaceuticals
10.12 Novartis
10.13 Pierre Fabre
10.14 Pfizer
10.15 Recombio
10.16 Roche Holding
10.17 Samsung Bioepis
10.18 Synthon
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies
2. NEED FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
3. BREAST CANCER MONOCLONAL ANTIBODIES MECHANISM
4. GLOBAL BREAST CANCER MONOCLONAL ANTIBODY MARKET ANALYSIS
4.1 Current Market Scenario
4.2 Breast Cancer Pipeline Overview
5. GLOBAL BREAST CANCER MONOCLONAL ANTIBODY MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. GLOBAL BREAST CANCER MONOCLONAL ANTIBODIES MARKET FUTURE PROSPECTS
7. BREAST CANCER MONOCLONAL ANTIBODIES PIPELINE BY COMPANY & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase III
7.9 Registered
8. MARKETED BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
8.1 Bevacizumab (Avastin)
8.2 Pertuzumab (Omnitarg, Perjeta)
8.3 Trastuzumab (Herceptin)
8.4 Trastuzumab Biosimilar (Hertraz & CANMAb)
8.5 Trastuzumab Emtansine (Kadcyla)
8.6 Trastuzumab Subcutaneous (Herceptin)
9. DISCONTINUED & SUSPENDED BREAST CANCER MONOCLONAL ANTIBODIES PIPELINE BY COMPANY & PHASE
9.1 Discontinued
9.2 No Development Reported
10. COMPETITIVE LANDSCAPE
10.1 Amgen
10.2 Biocad
10.3 Biocon
10.4 Celltrion Pharm
10.5 CuraGen Corporation
10.6 Dyax Corp
10.7 GlaxoSmithKline
10.8 ImmunoGen
10.9 MacroGenics
10.10 Merck
10.11 Merrimack Pharmaceuticals
10.12 Novartis
10.13 Pierre Fabre
10.14 Pfizer
10.15 Recombio
10.16 Roche Holding
10.17 Samsung Bioepis
10.18 Synthon
LIST OF FIGURES
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 3-1: Mechanism of Bevacizumab
Figure 3-2: Mechanism of Denosumab
Figure 3-3: Mechanism of Trastuzumab
Figure 3-4: Mechanism of Trastuzumab Emtansine
Figure 3-5: Mechanism of Pertuzumab
Figure 4-1: Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-2: Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 5-1: Global Breast Cancer Monoclonal Antibody Market Favorable Parameters
Figure 5-2: Breast Cancer Monoclonal Antibodies Commercialization Challenges
Figure 10-1: Amgen Clinical Pipeline
Figure 10-2: Biocon Clinical Pipeline
Figure 10-3: Celltrion Clinical Pipeline
Figure 10-4: MacroGenics Clinical Pipeline
Figure 10-5: Novartis Clinical Pipeline
Figure 10-6: Synthon Clinical Pipeline
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 3-1: Mechanism of Bevacizumab
Figure 3-2: Mechanism of Denosumab
Figure 3-3: Mechanism of Trastuzumab
Figure 3-4: Mechanism of Trastuzumab Emtansine
Figure 3-5: Mechanism of Pertuzumab
Figure 4-1: Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-2: Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 5-1: Global Breast Cancer Monoclonal Antibody Market Favorable Parameters
Figure 5-2: Breast Cancer Monoclonal Antibodies Commercialization Challenges
Figure 10-1: Amgen Clinical Pipeline
Figure 10-2: Biocon Clinical Pipeline
Figure 10-3: Celltrion Clinical Pipeline
Figure 10-4: MacroGenics Clinical Pipeline
Figure 10-5: Novartis Clinical Pipeline
Figure 10-6: Synthon Clinical Pipeline
LIST OF TABLES
Table 2-1: Breast Cancer Monoclonal Antibodies Available in Global Market
Table 2-2: Herceptin Biosimilars Available in Global Market
Table 2-1: Breast Cancer Monoclonal Antibodies Available in Global Market
Table 2-2: Herceptin Biosimilars Available in Global Market
